Anchor Capital Advisors LLC Has $46.59 Million Stock Holdings in Solventum Corporation $SOLV

Anchor Capital Advisors LLC reduced its position in shares of Solventum Corporation (NYSE:SOLV) by 1.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 587,922 shares of the company’s stock after selling 9,989 shares during the period. Solventum makes up approximately 1.3% of Anchor Capital Advisors LLC’s investment portfolio, making the stock its 26th biggest position. Anchor Capital Advisors LLC owned 0.34% of Solventum worth $46,587,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Hilltop National Bank boosted its stake in Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new position in Solventum during the 3rd quarter worth approximately $25,000. JNBA Financial Advisors lifted its stake in Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares during the last quarter. CYBER HORNET ETFs LLC acquired a new stake in Solventum in the second quarter valued at approximately $28,000. Finally, City State Bank boosted its position in Solventum by 166.7% in the fourth quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after buying an additional 240 shares in the last quarter.

Insider Buying and Selling at Solventum

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.24% of the stock is owned by corporate insiders.

Solventum Price Performance

Shares of NYSE SOLV opened at $76.40 on Wednesday. The company has a market capitalization of $13.23 billion, a PE ratio of 9.36, a P/E/G ratio of 1.17 and a beta of 0.69. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20. The firm has a fifty day simple moving average of $69.75 and a 200 day simple moving average of $75.08.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the business posted $1.34 EPS. The business’s revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, sell-side analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SOLV shares. Rothschild & Co Redburn started coverage on Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective on the stock. Piper Sandler cut their price target on Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Wedbush initiated coverage on Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 price objective for the company. Finally, Wells Fargo & Company cut their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Solventum currently has a consensus rating of “Moderate Buy” and an average target price of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.